PG
ITCI

PEAK6 Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

PEAK6 Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,400
Closed -$96K – 5382
2015
Q3 		$96K Buy
+2,400
New +$78.3K ﹤0.01% 4338

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

PEAK6 Group's ITCI Position: Q4 2015 in Review

PEAK6 Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2015, closing a stake of 2,400 shares — an estimated $96K sold.

PEAK6 Group first reported a position in ITCI in Q3 2015 and held it in 1 quarter. The position peaked at $96K in Q3 2015. 132 funds tracked by Wall St. Rank hold ITCI as of Q4 2015.

  • PEAK6 Group reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2015 after selling out during the quarter.
  • PEAK6 Group sold 2,400 Intra-Cellular Therapies Inc. shares in Q4 2015, an estimated $96K.
  • PEAK6 Group first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 1 quarter.
  • PEAK6 Group's Intra-Cellular Therapies Inc. position peaked at $96K in Q3 2015.
  • 132 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2015.

Based on PEAK6 Group's 13F filing for Q4 2015, filed 16 Feb 2016.